Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This p...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-11-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-01050-7 |
| _version_ | 1797415956638597120 |
|---|---|
| author | Shan Jing Yang Lin Randy Dockens David Marchisin Bing He Ihab G. Girgis Anjaneya Chimalakonda Bindu Murthy Urvi Aras |
| author_facet | Shan Jing Yang Lin Randy Dockens David Marchisin Bing He Ihab G. Girgis Anjaneya Chimalakonda Bindu Murthy Urvi Aras |
| author_sort | Shan Jing |
| collection | DOAJ |
| description | Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This phase I, double-blind, single-/multiple-dose study randomized healthy Chinese subjects 4:1 to a single dose of deucravacitinib 6 mg or placebo (group 1) or deucravacitinib 12 mg or placebo (group 2) on day 1; groups 1 and 2 received deucravacitinib 6 mg and 12 mg once daily, respectively, or placebo on days 5–19. Blood samples were collected on days 1–5 (0 predose–96 h postdose), day 5 (0–24 h postdose), days 9 and 12 (0 h), and day 19 (0–24 h postdose). Deucravacitinib and metabolite (BMT-153261, BMT-158170) concentrations were determined using liquid chromatography/mass spectrometry; pharmacokinetic parameters were calculated using noncompartmental analysis. Urine was collected on days 1–4 (4 h predose–96 h postdose). Safety was monitored throughout. Results Forty healthy Chinese subjects (groups 1 and 2: deucravacitinib, n = 32; placebo, n = 8) were enrolled. Deucravacitinib was rapidly absorbed after single-/multiple-dose administration, with median time to maximal plasma concentration of 1.5–2.3 h. Systemic exposure after single or multiple doses increased approximately twofold with twofold dose increase. Modest deucravacitinib accumulation was observed after multiple-dose administration (1.3- to 1.4-fold increase in area under the curve [AUC] under one dosing interval). Metabolite-to-parent ratios for maximal plasma concentration and AUC remained consistent in each dose group. Mean urinary percent recovery and renal clearance were similar between dose groups. Most adverse events (AEs) were mild/moderate, with no serious treatment-related AEs, deaths, or discontinuations due to AEs. Conclusion Deucravacitinib was safe and well tolerated in healthy Chinese subjects. Deucravacitinib exhibited rapid absorption, dose-related increases in exposure, comparable half-life, and no evidence of time-dependent pharmacokinetics, suggesting minimal effect of Chinese ethnicity on deucravacitinib pharmacokinetics. Clinical Trial Registration NCT03956953. |
| first_indexed | 2024-03-09T05:56:55Z |
| format | Article |
| id | doaj.art-138681b5e9fe48568e696414c32c2790 |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-09T05:56:55Z |
| publishDate | 2023-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-138681b5e9fe48568e696414c32c27902023-12-03T12:12:28ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-11-0113123153316410.1007/s13555-023-01050-7Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese SubjectsShan Jing0Yang Lin1Randy Dockens2David Marchisin3Bing He4Ihab G. Girgis5Anjaneya Chimalakonda6Bindu Murthy7Urvi Aras8Clinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical UniversityClinical Pharmacology Centre, Beijing Anzhen Hospital, Capital Medical UniversityBristol Myers SquibbBristol Myers SquibbBristol Myers SquibbBristol Myers SquibbBristol Myers SquibbBristol Myers SquibbBristol Myers SquibbAbstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This phase I, double-blind, single-/multiple-dose study randomized healthy Chinese subjects 4:1 to a single dose of deucravacitinib 6 mg or placebo (group 1) or deucravacitinib 12 mg or placebo (group 2) on day 1; groups 1 and 2 received deucravacitinib 6 mg and 12 mg once daily, respectively, or placebo on days 5–19. Blood samples were collected on days 1–5 (0 predose–96 h postdose), day 5 (0–24 h postdose), days 9 and 12 (0 h), and day 19 (0–24 h postdose). Deucravacitinib and metabolite (BMT-153261, BMT-158170) concentrations were determined using liquid chromatography/mass spectrometry; pharmacokinetic parameters were calculated using noncompartmental analysis. Urine was collected on days 1–4 (4 h predose–96 h postdose). Safety was monitored throughout. Results Forty healthy Chinese subjects (groups 1 and 2: deucravacitinib, n = 32; placebo, n = 8) were enrolled. Deucravacitinib was rapidly absorbed after single-/multiple-dose administration, with median time to maximal plasma concentration of 1.5–2.3 h. Systemic exposure after single or multiple doses increased approximately twofold with twofold dose increase. Modest deucravacitinib accumulation was observed after multiple-dose administration (1.3- to 1.4-fold increase in area under the curve [AUC] under one dosing interval). Metabolite-to-parent ratios for maximal plasma concentration and AUC remained consistent in each dose group. Mean urinary percent recovery and renal clearance were similar between dose groups. Most adverse events (AEs) were mild/moderate, with no serious treatment-related AEs, deaths, or discontinuations due to AEs. Conclusion Deucravacitinib was safe and well tolerated in healthy Chinese subjects. Deucravacitinib exhibited rapid absorption, dose-related increases in exposure, comparable half-life, and no evidence of time-dependent pharmacokinetics, suggesting minimal effect of Chinese ethnicity on deucravacitinib pharmacokinetics. Clinical Trial Registration NCT03956953.https://doi.org/10.1007/s13555-023-01050-7Chinese subjectsDeucravacitinibPharmacokineticsPsoriasisSafetyTyrosine kinase 2 inhibitor |
| spellingShingle | Shan Jing Yang Lin Randy Dockens David Marchisin Bing He Ihab G. Girgis Anjaneya Chimalakonda Bindu Murthy Urvi Aras Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects Dermatology and Therapy Chinese subjects Deucravacitinib Pharmacokinetics Psoriasis Safety Tyrosine kinase 2 inhibitor |
| title | Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects |
| title_full | Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects |
| title_fullStr | Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects |
| title_full_unstemmed | Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects |
| title_short | Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects |
| title_sort | pharmacokinetics and safety of the tyrosine kinase 2 inhibitor deucravacitinib in healthy chinese subjects |
| topic | Chinese subjects Deucravacitinib Pharmacokinetics Psoriasis Safety Tyrosine kinase 2 inhibitor |
| url | https://doi.org/10.1007/s13555-023-01050-7 |
| work_keys_str_mv | AT shanjing pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT yanglin pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT randydockens pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT davidmarchisin pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT binghe pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT ihabggirgis pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT anjaneyachimalakonda pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT bindumurthy pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects AT urviaras pharmacokineticsandsafetyofthetyrosinekinase2inhibitordeucravacitinibinhealthychinesesubjects |